Document is current
Any future updates will be listed below
-
Authors
Chiou, Shene https://orcid.org/0000-0003-1295-2183
Cawthorne, Wayne https://orcid.org/0009-0001-8467-8091
Soerianto, Thomas https://orcid.org/0009-0005-0452-7074
Hofferek, Vinzenz https://orcid.org/0000-0002-6150-1453
Patel, Komal M.
Garnish, Sarah E.
Tovey Crutchfield, Emma C. https://orcid.org/0000-0003-0379-2931
Hall, Cathrine
Hildebrand, Joanne M. https://orcid.org/0000-0002-1456-2042
McConville, Malcolm J. https://orcid.org/0000-0002-7107-7887
Lawlor, Kate E. https://orcid.org/0000-0003-0471-6842
Hawkins, Edwin D. https://orcid.org/0000-0002-3686-8261
Samson, Andre L. https://orcid.org/0000-0002-0637-2716
Murphy, James M. https://orcid.org/0000-0003-0195-3949
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1172929, 9000719)
- License Information
-
More Information
Article History
Received: 29 October 2024
Revised: 9 November 2024
Accepted: 11 November 2024
First Online: 21 November 2024
Competing interests
: KMP, JMH, KEL, ALS, and JMM contribute to or have contributed to a project developing necroptosis inhibitors in collaboration with Anaxis Pharma. The other authors declare no competing interests.
: All experiments were approved by the WEHI Animal Ethics Committee following the Prevention of Cruelty to Animals Act (1996) and the Australian National Health and Medical Research Council Code of Practice for the Care and Use of Animals for Scientific Purposes (1997).
